{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RRMM&page=3", "query": { "condition": "RRMM", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 86, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RRMM&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RRMM&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:24:04.175Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07727668", "title": "Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma", "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "CAR-T Leukapheresis", "type": "PROCEDURE" }, { "name": "CAR-T Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Shambavi Richard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-07", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07727668" }, { "nct_id": "NCT07222761", "title": "A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-01-02", "completion_date": "2034-08-23", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York • Columbus, Ohio + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222761" }, { "nct_id": "NCT07082270", "title": "Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Selvigaltin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-04-01", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07082270" }, { "nct_id": "NCT07217119", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Feladilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-11-26", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Madison, Wisconsin", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217119" }, { "nct_id": "NCT05651932", "title": "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma", "Myeloma Multiple" ], "interventions": [ { "name": "Cohort A1 & A2: KTX-1001", "type": "DRUG" }, { "name": "Cohort B1 & B2: KTX-1001+Mezigdomide", "type": "DRUG" }, { "name": "Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)", "type": "DRUG" }, { "name": "Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-02-22", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 19, "location_summary": "San Francisco, California • Jacksonville, Florida • Miami, Florida + 15 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651932" }, { "nct_id": "NCT03143985", "title": "Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Koen van Besien", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-07-21", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03143985" }, { "nct_id": "NCT07382739", "title": "A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Phase 2", "Radiotherapy-Induced Immune Priming", "Elranatamab", "Relapsed Refractory Multiple Myeloma (RRMM)", "Extramedullary Disease in Multiple Myeloma", "Paramedullary Disease", "PMD" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 34, "start_date": "2026-03-31", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07382739" }, { "nct_id": "NCT04162210", "title": "Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pom/dex (Pomalidomide plus low dose Dexamethasone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2020-04-02", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 10, "location_summary": "Tucson, Arizona • Pueblo, Colorado • Detroit, Michigan + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Clifton Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04162210" }, { "nct_id": "NCT07740317", "title": "Neurocognitive Trajectories After BCMA CAR-T", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma (MM)", "CART Therapy", "Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Standardized neurocognitive testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-11", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07740317" }, { "nct_id": "NCT07280013", "title": "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Cemsidomide", "type": "DRUG" }, { "name": "Elranatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-06", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-10-30T17:24:04.175Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Sacramento, California • Santa Monica, California + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07280013" } ] }